Reduced efficacy of sumatriptan in XXXX .

@entity2795 @entity1 @entity5330 @entity2704 @entity158
OBJECTIVE: To determine whether acute @entity2704 treatment outcome is different in @entity2795 compared with @entity5330 . METHODS: We examined pooled outcome data for sumatriptan treatment of @entity2704 with and without aura from the sumatriptan/naratriptan aggregate @entity1 database. We also examined similar outcome data for inhaled dihydroergotamine (DHE) from a single, large randomized controlled study. RESULTS: The pooled @entity158 -free rates 2 hours postdose for sumatriptan 100 mg were significantly higher in @entity1 treating attacks without aura (32%) compared with the group who treated attacks with aura (24%) (p < 0.001). The relative risk for @entity158 freedom 2 hours postdose for attacks without aura was 1.33 (95% confidence interval: 1.16-1.54). The number needed to treat for 2 hours of @entity158 freedom was 4.4 for attacks without aura and 6.2 for attacks with aura. For the clinical trial of DHE, the 2-hour @entity158 -free rates did not differ between @entity1 treating attacks without aura (29.4%) compared with those who treated attacks with aura (27.2%; p = 0.65). The relative risk for @entity158 freedom 2 hours postdose for attacks without aura vs with aura was 1.08 (95% confidence interval: 0.77-1.53). The number needed to treat for 2 hours @entity158 free was 5.8 for attacks without aura and 5.0 for attacks with aura. CONCLUSION: This post hoc analysis of pooled data from multiple randomized trials indicates that sumatriptan is less effective as acute therapy for @entity2704 attacks with aura compared with attacks without aura. In the single study of inhaled DHE, the treatment had similar efficacy for @entity2704 attacks with and without aura. Different responses of @entity2704 with vs without aura to acute therapies may provide insight into underlying @entity2704 mechanisms and influence the choice of acute therapies for different types of @entity2704 attacks.
